

William C Cushman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1034865/publications.pdf>

Version: 2024-02-01

55
papers

19,406
citations

147786

31
h-index

168376

53
g-index

55
all docs

55
docs citations

55
times ranked

18954
citing authors

#	ARTICLE	IF	CITATIONS
1	2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. JAMA - Journal of the American Medical Association, 2014, 311, 507.	7.4	6,625
2	A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine, 2015, 373, 2103-2116.	27.0	4,880
3	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2010, 362, 1575-1585.	27.0	3,117
4	Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 553.	7.4	786
5	KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International, 2021, 99, S1-S87.	5.2	497
6	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). Clinical Trials, 2014, 11, 532-546.	1.6	408
7	Effects of Intensive BP Control in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 2812-2823.	6.1	364
8	Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA - Journal of the American Medical Association, 2019, 322, 524.	7.4	285
9	Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine, 2021, 384, 1921-1930.	27.0	214
10	Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease. Hypertension, 2014, 64, 1012-1021.	2.7	196
11	Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension, 2018, 71, 848-857.	2.7	190
12	Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International, 2021, 99, 559-569.	5.2	169
13	Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure. Hypertension, 2017, 69, 42-50.	2.7	143
14	Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. Circulation, 2018, 137, 134-143.	1.6	134
15	Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension. Circulation, 2017, 136, 440-450.	1.6	118
16	Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension. Hypertension, 2021, 77, 692-705.	2.7	112
17	Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial. Hypertension, 2016, 68, 888-895.	2.7	103
18	Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. Circulation: Heart Failure, 2017, 10, .	3.9	88

#	ARTICLE	IF	CITATIONS
19	SPRINT Trial Results. Hypertension, 2016, 67, 263-265.	2.7	79
20	Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. Journal of the American Heart Association, 2018, 7, e009326.	3.7	79
21	Research Needs to Improve Hypertension Treatment and Control in African Americans. Hypertension, 2016, 68, 1066-1072.	2.7	78
22	The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure. Hypertension, 2016, 68, 39-45.	2.7	77
23	Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.7	76
24	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care, 2017, 40, 1401-1408.	8.6	68
25	Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events. Hypertension, 2020, 75, 660-667.	2.7	57
26	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. Journal of the American Society of Hypertension, 2016, 10, 847-856.	2.3	56
27	Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation, 2011, 124, 1811-1818.	1.6	49
28	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. Annals of Internal Medicine, 2021, 174, 58-68.	3.9	47
29	Association of Medical Treatment Nonadherence With All-Cause Mortality in Newly Treated Hypertensive US Veterans. Hypertension, 2014, 64, 951-957.	2.7	45
30	Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. American Journal of Nephrology, 2016, 43, 271-280.	3.1	43
31	Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 1270-1281.	3.9	41
32	Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. Hypertension, 2016, 67, 550-555.	2.7	17
33	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes and Endocrinology, the, 2021, 9, 484-490.	11.4	17
34	This synopsis summarizes key features of a joint VA/DoD guideline on diagnosis and management of hypertension in the primary care setting.. Annals of Internal Medicine, 2020, 173, 904-913.	3.9	14
35	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1345-1351.	3.6	14
36	Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. Journal of the American College of Cardiology, 2021, 77, 1977-1990.	2.8	14

#	ARTICLE	IF	CITATIONS
37	The Benefits of Intensive Versus Standard Blood Pressure Treatment According to Fine Particulate Matter Air Pollution Exposure. <i>Hypertension</i> , 2021, 77, 813-822.	2.7	13
38	A Method to Quantify Mean Hypertension Treatment Daily Dose Intensity Using Health Care System Data. <i>JAMA Network Open</i> , 2021, 4, e2034059.	5.9	9
39	Incidence and Outcomes of Acute Heart Failure With Preserved Versus Reduced Ejection Fraction in SPRINT. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008322.	3.9	9
40	Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Network Open</i> , 2022, 5, e2143001.	5.9	9
41	Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VA's Diuretic Comparison Project. <i>Contemporary Clinical Trials</i> , 2022, 116, 106754.	1.8	9
42	SPRINT Revisited: Updated Results and Implications. <i>Hypertension</i> , 2021, 78, 1701-1710.	2.7	9
43	Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood) Tj ETQq1 1 0.784314 rgBT /Overl	1.9	8
44	Racial/ethnic disparities in measure calculations for Part D Star Ratings among Medicare beneficiaries with diabetes, hypertension, and/or hyperlipidemia. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1469-1477.	3.0	8
45	Heart Failure Prevention in Older Patients Using Intensive Blood Pressure Reduction. <i>JACC: Heart Failure</i> , 2019, 7, 1032-1041.	4.1	7
46	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. <i>American Journal of Cardiology</i> , 2018, 122, 1496-1505.	1.6	6
47	Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults. <i>Annals of Internal Medicine</i> , 2021, 174, 1666-1673.	3.9	6
48	A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. <i>Journal of Hypertension</i> , 2018, 36, 947-956.	0.5	4
49	Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. <i>Journal of the National Medical Association</i> , 2017, 109, 172-181.	0.8	3
50	Real-World Evidence Supports Optimally Dosed Thiazide-Type Diuretics As Preferred in Treatment Regimens of Older Adults with Hypertension. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1045-1047.	2.6	2
51	Estimating Systolic Blood Pressure Intervention Trial Participant Posttrial Survival Using Pooled Epidemiologic Cohort Data. <i>Journal of the American Heart Association</i> , 2021, 10, e020361.	3.7	2
52	Antihypertensive Medication Adherence, Stroke and Death. <i>Journal of General Internal Medicine</i> , 2010, 25, 764-764.	2.6	1
53	Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 142-149.	1.5	1
54	Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults. <i>Annals of Internal Medicine</i> , 2022, 175, W15-W16.	3.9	0

#	ARTICLE	IF	CITATIONS
55	Blood Pressure Control in Hispanic Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).. Circulation, 2001, 103, 1348-1348.	1.6	0